PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: ARV-471 (PF-07850327)
Drug: Letrozole
Combination Product: Palbociclib

First Posted Date: 2023-06-18

Last Posted Date: 2025-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT05909397

Locations: 🇸🇰
Nemocnica na okraji mesta n o, Partizanske, Slovakia
🇺🇸
BRCR Medical Center Inc, Plantation, Florida, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

and more 25 locations

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07293893
Drug: Placebo

First Posted Date: 2023-06-18

Last Posted Date: 2025-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05907395

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1

Withdrawn

Conditions: Non-small Cell Lung Cancer (NSCLC)
Solid Tumors
Breast Cancer
Ovarian Cancer
Liposarcoma
Endometrial

Interventions: Drug: PF-07224826
Combination Product: Fulvestrant

First Posted Date: 2023-06-15

Last Posted Date: 2023-11-08

Lead Sponsor: Pfizer

Registration Number: NCT05905341

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

Phase 1

Completed

Conditions: Pharmacokinetics
Healthy Volunteers

Interventions: Drug: Rosuvastatin
Drug: Nirmatrelvir/ritonavir

First Posted Date: 2023-06-12

Last Posted Date: 2024-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05898672

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Phase 1

Completed

Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)

Interventions: Biological: RSVpreF 120 µg
Biological: RSVpreF 60 µg

First Posted Date: 2023-06-12

Last Posted Date: 2025-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT05900154

Locations: 🇺🇸
Senders Pediatrics, South Euclid, Ohio, United States
🇺🇸
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 14 locations

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Phase 1

Completed

Conditions: Multiple Myeloma
Non-Hodgkin Lymphoma

Interventions: Drug: Maplirpacept

First Posted Date: 2023-06-09

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05896774

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

and more 2 locations

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Phase 3

Recruiting

Conditions: Myositis

Interventions: Drug: PF-06823859
Drug: Placebo

First Posted Date: 2023-06-09

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 270

Registration Number: NCT05895786

Locations: 🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States
🇺🇸
Arizona Arthritis & Rheumatology Associates, P.C., Glendale, Arizona, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 120 locations

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: maplirpacept (PF-07901801)
Drug: Glofitamab
Drug: Obinutuzumab

First Posted Date: 2023-06-09

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 70

Registration Number: NCT05896163

Locations: 🇦🇺
Epworth Freemasons, Melbourne, Victoria, Australia
🇦🇺
Slade Pharmacy, Richmond, Victoria, Australia
🇮🇱
Sourasky Medical Center, Tel Aviv, Tell Abīb, Israel

and more 22 locations

A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Device: Smartclic

First Posted Date: 2023-06-07

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05891600

Locations: 🇨🇴
Biomab Ips S.A.S., Bogota, Colombia

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07853578
Drug: Placebo

First Posted Date: 2023-06-06

Last Posted Date: 2025-01-03

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT05890105

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy